Ideaya Biosciences Inc Cash Flow Conversion Efficiency
Ideaya Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) has a cash flow conversion efficiency ratio of -0.136x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-163.38 Million) by net assets ($1.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ideaya Biosciences Inc (2017–2025)
Cash flow conversion efficiency of Ideaya Biosciences Inc from 2017 to 2025. This chart illustrates how Ideaya Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ideaya Biosciences Inc (IDYA) share price today for real-time trading data and today's change.
Ideaya Biosciences Inc Cash Flow Conversion Ratio Explained
Ideaya Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ideaya Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ideaya Biosciences Inc ranked by their cash flow conversion efficiency. Also see IDYA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clas Ohlson AB (publ)
ST:CLAS-B
|
0.190x |
|
TechCreate Group Ltd.
NYSE MKT:TCGL
|
0.526x |
|
Infore Environment Technology Group Co Ltd
SHE:000967
|
-0.009x |
|
FIT Hon Teng Limited
F:0FJ
|
0.040x |
|
Magnite Inc
NASDAQ:MGNI
|
0.199x |
|
Sigma Advanced Systems Limited
NSE:MEGASOFT
|
-0.777x |
|
Catcher Technology Co Ltd
TW:2474
|
0.011x |
|
China National Medicines Corp Ltd
SHG:600511
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Ideaya Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Ideaya Biosciences Inc from 2017 to 2025. Review Ideaya Biosciences Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.02 Billion | $-71.10 Million | -0.070x | +70.27% |
| 2024-12-31 | $1.06 Billion | $-247.58 Million | -0.234x | -26.00% |
| 2023-12-31 | $621.09 Million | $-115.22 Million | -0.186x | +25.63% |
| 2022-12-31 | $349.45 Million | $-87.17 Million | -0.249x | -34.85% |
| 2021-12-31 | $301.51 Million | $-55.78 Million | -0.185x | -166.13% |
| 2020-12-31 | $198.27 Million | $55.46 Million | 0.280x | +171.44% |
| 2019-12-31 | $100.40 Million | $-39.31 Million | -0.392x | -169.39% |
| 2018-12-31 | $-48.95 Million | $-27.62 Million | 0.564x | -27.35% |
| 2017-12-31 | $-15.74 Million | $-12.22 Million | 0.777x | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more